Actualités

Les sociétés du Portfeuille

» 19/12/03
France Biotech se réjouit de l'adoption du statut de la jeune entreprise innovante dans la loi de finance 2004

» 12/12/03
Pixantrone Induces Impressive 77% Major Tumor Response Rate in Patients with Relapsed Aggressive Lymphoma when Substituted for Doxorubicin in CHOP Regimen

» 10/12/03
Addex Pharmaceuticals SA Signs Three year Clinical Development Partnership with Fulcrum Pharma

» 02/12/03
The pharmaceutical company Biolipox strengthens Board of Directors with a well known industrialist

» 25/11/03
IDM obtient un deuxième brevet au Japon

» 19/11/03
Allergan et Exonhit initient leur premier criblage à haut flux sur une cible identifiée conjointement

» 14/11/03
Innate Pharma and Novo Nordisk A/S sign licensing deal which opensnew avenue in cancer immunotherapy

» 13/11/03
Esmertec Nets €23m in Over-Subscribed Funding Round

» 28/10/03
Cellzome Announces Research Collaboration with Johnson & Johnson R&D

» 23/10/03
Cell Therapeutics, Inc. and Novuspharma S.p.A Announce Shareholder Approval of Merger

» 30/09/03
Novuspharma Press Release: Financial Results for the nine months ended 30 September 2003

» 10/09/03
Neuro3d raises M€ 10 from Existing Shareholders

» 02/09/03
Ingenium Appoints Dr. Klaus Dembowsky to Vice President Drug Discovery

» 30/06/03
Q2 Another Record for AtomZ

» 07/08/03
Novuspharma SpA Announces Financial Results for the Six Months Ended 30 June 2003

» 28/07/03
Servista enables Lloyds TSB to launch home energy and telephone services

» 07/07/03
NovusPharma’s Pixantrone Regimen produces high response rates in relapsed aggressive lymphoma

» 17/06/03
Cell Therapeutics, Inc. (CTI) Adds Pixantrone to its Oncology Drug Pipeline and Extends Global Cancer Business through Merger with Novuspharma S.p.a.

» 14/05/03
Novuspharma SpA Announces Financial Results for the Three Months Ended 31 March 2003

» 02/05/03
Ingenium publishes in Science groundbreaking results about the pathogenetic cause for motor neuron disease

» 17/04/03
Diatos expands its management team

» 25/02/03
ESMERTEC acquires Insignia JVM business assets and becomes master distributor of Insignia’s Java Virtual Machine solution e

Découvrez le site Sofinnova Ventures, notre société soeur a San Francisco http://www.sofinnova.com